Pieris Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Palvella Therapeutics

10/05/2023 14:33

* Pieris Pharmaceuticals Inc  PIRS.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
March. The mean expectation of two analysts for the quarter was
for a loss of 14 cents per share.
    * Revenue fell 82.4% to $1.94 million from a year ago;
analysts
expected $6.51 million. 
    * Pieris Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 18 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Pieris Pharmaceuticals Inc shares had fallen by 12.9% this
quarter and lost 18.3% so far this year.
    * The company reported a quarterly loss of $13.18 million.
    * Wall Street's median 12-month price target for Pieris
Pharmaceuticals Inc is $7.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.14          -0.18          Missed
 Dec. 31 2022      -0.23          -0.11          Beat
 Sep. 30 2022      -0.16          -0.13          Beat
 Jun. 30 2022      -0.11          -0.14          Missed